BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lu D, Immadi SS, Wu Z, Kendall DA. Translational potential of allosteric modulators targeting the cannabinoid CB1 receptor. Acta Pharmacol Sin 2019;40:324-35. [PMID: 30333554 DOI: 10.1038/s41401-018-0164-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Garai S, Schaffer PC, Laprairie RB, Janero DR, Pertwee RG, Straiker A, Thakur GA. Design, synthesis, and pharmacological profiling of cannabinoid 1 receptor allosteric modulators: Preclinical efficacy of C2-group GAT211 congeners for reducing intraocular pressure. Bioorg Med Chem 2021;50:116421. [PMID: 34634617 DOI: 10.1016/j.bmc.2021.116421] [Reference Citation Analysis]
2 Yang X, Wang X, Xu Z, Wu C, Zhou Y, Wang Y, Lin G, Li K, Wu M, Xia A, Liu J, Cheng L, Zou J, Yan W, Shao Z, Yang S. Molecular mechanism of allosteric modulation for the cannabinoid receptor CB1. Nat Chem Biol. [DOI: 10.1038/s41589-022-01038-y] [Reference Citation Analysis]
3 Wu J. Cannabis, cannabinoid receptors, and endocannabinoid system: yesterday, today, and tomorrow. Acta Pharmacol Sin 2019;40:297-9. [PMID: 30670816 DOI: 10.1038/s41401-019-0210-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 11.0] [Reference Citation Analysis]
4 Miceli M, Casati S, Allevi P, Berra S, Ottria R, Rota P, Branchini BR, Ciuffreda P. A New Ultrasensitive Bioluminescence-Based Method for Assaying Monoacylglycerol Lipase. Int J Mol Sci 2021;22:6148. [PMID: 34200322 DOI: 10.3390/ijms22116148] [Reference Citation Analysis]
5 Raux PL, Drutel G, Revest JM, Vallée M. New perspectives on the role of the neurosteroid pregnenolone as an endogenous regulator of type-1 cannabinoid receptor (CB1R) activity and function. J Neuroendocrinol 2021;:e13034. [PMID: 34486765 DOI: 10.1111/jne.13034] [Reference Citation Analysis]
6 Schaffer PC, Kulkarni PM, Janero DR, Thakur GA. Focused structure-activity relationship profiling around the 2-phenylindole scaffold of a cannabinoid type-1 receptor agonist-positive allosteric modulator: site-III aromatic-ring congeners with enhanced activity and solubility. Bioorg Med Chem 2020;28:115727. [PMID: 33065437 DOI: 10.1016/j.bmc.2020.115727] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Aderibigbe AO, Pandey P, Doerksen RJ. Negative allosteric modulators of cannabinoid receptor 1: Ternary complexes including CB1, orthosteric CP55940 and allosteric ORG27569. J Biomol Struct Dyn 2021;:1-19. [PMID: 33480332 DOI: 10.1080/07391102.2021.1873187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Winters BL, Vaughan CW. Mechanisms of endocannabinoid control of synaptic plasticity. Neuropharmacology 2021;197:108736. [PMID: 34343612 DOI: 10.1016/j.neuropharm.2021.108736] [Reference Citation Analysis]
9 Rohbeck E, Eckel J, Romacho T. Cannabinoid Receptors in Metabolic Regulation and Diabetes. Physiology (Bethesda) 2021;36:102-13. [PMID: 33595385 DOI: 10.1152/physiol.00029.2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Garai S, Leo LM, Szczesniak AM, Hurst DP, Schaffer PC, Zagzoog A, Black T, Deschamps JR, Miess E, Schulz S, Janero DR, Straiker A, Pertwee RG, Abood ME, Kelly MEM, Reggio PH, Laprairie RB, Thakur GA. Discovery of a Biased Allosteric Modulator for Cannabinoid 1 Receptor: Preclinical Anti-Glaucoma Efficacy. J Med Chem 2021;64:8104-26. [PMID: 33826336 DOI: 10.1021/acs.jmedchem.1c00040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Seltzer ES, Watters AK, MacKenzie D Jr, Granat LM, Zhang D. Cannabidiol (CBD) as a Promising Anti-Cancer Drug. Cancers (Basel) 2020;12:E3203. [PMID: 33143283 DOI: 10.3390/cancers12113203] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
12 Hryhorowicz S, Kaczmarek-Ryś M, Andrzejewska A, Staszak K, Hryhorowicz M, Korcz A, Słomski R. Allosteric Modulation of Cannabinoid Receptor 1-Current Challenges and Future Opportunities. Int J Mol Sci 2019;20:E5874. [PMID: 31771126 DOI: 10.3390/ijms20235874] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
13 Laprairie RB, Mohamed KA, Zagzoog A, Kelly MEM, Stevenson LA, Pertwee R, Denovan-Wright EM, Thakur GA. Indomethacin Enhances Type 1 Cannabinoid Receptor Signaling. Front Mol Neurosci 2019;12:257. [PMID: 31680861 DOI: 10.3389/fnmol.2019.00257] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
14 Jakowiecki J, Abel R, Orzeł U, Pasznik P, Preissner R, Filipek S. Allosteric Modulation of the CB1 Cannabinoid Receptor by Cannabidiol-A Molecular Modeling Study of the N-Terminal Domain and the Allosteric-Orthosteric Coupling. Molecules 2021;26:2456. [PMID: 33922473 DOI: 10.3390/molecules26092456] [Reference Citation Analysis]
15 Seillier A. The endocannabinoid system as a therapeutic target for schizophrenia: Failures and potentials. Neurosci Lett 2021;759:136064. [PMID: 34146641 DOI: 10.1016/j.neulet.2021.136064] [Reference Citation Analysis]